In two trials of over 1,200 premenopausal women with low sexual desire, bremelanotide increased desire scores by 0.5 points versus 0.2 with placebo (p < 0.001), with benefits appearing within the first few weeks and maintained over 6 months.
Source: Kingsberg et al., "Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials," Obstetrics & Gynecology (2019) — the RECONNECT Trials












